Catalent and Stirling Ultracold partner on energy-efficient cold chains


The company has agreed to use Stirling's ULT freezers that use 100% natural refrigerants and around 30% of the carbon dioxide during operation compared with legacy ULT freezers

Catalent and Stirling Ultracold, the innovative developer and manufacturer of ultra-low temperature (ULT) freezers for life science and biopharma research, have announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across Catalent's multiple business units.

The growth of biopharmaceuticals and newer modalities within pharmaceutical research and development has driven the need for Catalent to invest in a sustainable and reliable cold chain infrastructure, to ensure the preservation of biological and other highly temperature-sensitive materials.

The partnership with Stirling Ultracold has already seen the delivery and installation of over 200 state-of-the-art freezers, with a further 60 planned, into Catalent's clinical supply services and cell and gene therapy sites in the US, Europe, and Asia-Pacific.

Accommodating a wide temperature range from -20 degrees Celsius to -86 degrees Celsius, Stirling freezers use 100% natural refrigerants, and during a typical ten-year lifespan, they will produce around 30% of the carbon dioxide during operation compared with legacy ULT freezers.

"The growth of precision medicine makes an effective ultra-low temperature infrastructure a necessity for companies partnering with innovators," said Dusty Tenney, CEO of Stirling Ultracold. "The infrastructure we have created with Catalent, which it is deploying across its network, will facilitate the safe storage and handling of novel treatments, including personalised medicines for rare diseases, many of which have the potential to be life-saving or life-changing for patients."

Sign up for your free email newsletter

&"Catalent is focused on providing safe, reliable product supply, and has responded to the rapid growth in new therapeutic modalities such as cell and gene therapies with solutions and capacity to match the significant demand for these therapies," added Matt Blume, VP of Business Transformation for Catalent's Clinical Supply Services.